AU2001268474A1 - Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance - Google Patents

Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance

Info

Publication number
AU2001268474A1
AU2001268474A1 AU2001268474A AU6847401A AU2001268474A1 AU 2001268474 A1 AU2001268474 A1 AU 2001268474A1 AU 2001268474 A AU2001268474 A AU 2001268474A AU 6847401 A AU6847401 A AU 6847401A AU 2001268474 A1 AU2001268474 A1 AU 2001268474A1
Authority
AU
Australia
Prior art keywords
diabetes
treatment
type
insulin resistance
amp kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268474A
Inventor
William Winder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham Young University
Original Assignee
Brigham Young University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham Young University filed Critical Brigham Young University
Publication of AU2001268474A1 publication Critical patent/AU2001268474A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
AU2001268474A 2000-06-16 2001-06-14 Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance Abandoned AU2001268474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21247600P 2000-06-16 2000-06-16
US60212476 2000-06-16
PCT/US2001/019283 WO2001097816A1 (en) 2000-06-16 2001-06-14 Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance

Publications (1)

Publication Number Publication Date
AU2001268474A1 true AU2001268474A1 (en) 2002-01-02

Family

ID=22791180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268474A Abandoned AU2001268474A1 (en) 2000-06-16 2001-06-14 Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance

Country Status (2)

Country Link
AU (1) AU2001268474A1 (en)
WO (1) WO2001097816A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2192495B1 (en) 2002-03-21 2005-02-16 Universidad De Barcelona NEW THERAPEUTIC USE OF RIBOSIDE 5-AMINOIMIDAZOL-4-CARBOXAMIDE (ACADESIN).
US20070213295A1 (en) * 2006-01-16 2007-09-13 The Board Of Regents Of The University Of Texas System Methods and compositions for inducing torpor in a subject
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
US11834469B2 (en) 2018-08-06 2023-12-05 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs

Also Published As

Publication number Publication date
WO2001097816A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
HK1045111B (en) (3-trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin resistance and type 2 diabetes
EP1405859A4 (en) Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof and intermediate therefor
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
AU2001277741A1 (en) 2-aminopyridine compounds and use thereof as drugs
AU4072799A (en) 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
HUP0402236A3 (en) Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
HK1055674A1 (en) Drugs for complications of diabetes and neuropathyand utilization thereof
AP9901719A0 (en) Treatment of diabetes with thiazolidinedione and metormin
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU2001256757A1 (en) Agents for preventing or ameliorating insulin resistance and/or obesity
HUP0301230A3 (en) Phenylpyridazine derivatives and drugs containing the same
EG21712A (en) Treatment of insulin resistance
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
AU2002349299A1 (en) Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
HUP0600436A2 (en) Catheter composition and uses thereof
AU2001268474A1 (en) Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance
AU1027501A (en) Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies
AU4073299A (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
HK1042253A1 (en) Compounds and their therapeutic use with diabetic complications
AU4546699A (en) Stabilized carbon dioxide fluid composition and use thereof
AU2002313248A1 (en) Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor